| scholarly article | Q13442814 |
| editorial | Q871232 |
| P50 | author | Peter J. Hotez | Q7174738 |
| P2093 | author name string | Bernard Pecoul | |
| P2860 | cites work | Trachoma | Q56482142 |
| Partnering for better microbial diagnostics | Q80088987 | ||
| Government action needed to step up research and development for world's most neglected diseases | Q81529523 | ||
| Global programme to eliminate lymphatic filariasis | Q81958764 | ||
| Buruli ulcer | Q83638686 | ||
| Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal | Q21144535 | ||
| Neglected infections of poverty in the United States of America | Q21144547 | ||
| The genome of the blood fluke Schistosoma mansoni | Q22122228 | ||
| The antipoverty vaccines | Q24290719 | ||
| Rescuing the bottom billion through control of neglected tropical diseases | Q24290723 | ||
| Identification of oxadiazoles as new drug leads for the control of schistosomiasis | Q24642230 | ||
| Current status of vaccines for schistosomiasis | Q24657733 | ||
| Opisthorchis viverrini: the carcinogenic human liver fluke | Q24658412 | ||
| "Rapid-impact interventions": how a policy of integrated control for Africa's neglected tropical diseases could benefit the poor | Q24810845 | ||
| Visceral leishmaniasis: new health tools are needed | Q24815791 | ||
| The global campaign to eliminate leprosy | Q25255463 | ||
| Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria | Q25256957 | ||
| The new anthelmintic tribendimidine is an L-type (levamisole and pyrantel) nicotinic acetylcholine receptor agonist | Q27306806 | ||
| Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening | Q27306843 | ||
| Elimination of dengue by community programs using Mesocyclops(Copepoda) against Aedes aegypti in central Vietnam | Q28236642 | ||
| Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial | Q28250035 | ||
| Developments in the treatment of visceral leishmaniasis | Q28256441 | ||
| A business plan to help the 'global South' in its fight against neglected diseases | Q28263529 | ||
| Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis | Q28277486 | ||
| Bacillus thuringiensis Cry5B protein is highly efficacious as a single-dose therapy against an intestinal roundworm infection in mice | Q28473074 | ||
| Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Médecins Sans Frontières | Q28475694 | ||
| Neglected infections of poverty among the indigenous peoples of the arctic | Q28749187 | ||
| Neglected Diseases Amid Wealth In The United States And Europe | Q29032269 | ||
| Control of neglected tropical diseases | Q29547285 | ||
| Drug resistance in leishmaniasis | Q29616242 | ||
| Comparative genomics of trypanosomatid parasitic protozoa | Q29617953 | ||
| Vaccine prospects for amebiasis | Q30438347 | ||
| Eliminating lymphatic filariasis, onchocerciasis, and schistosomiasis from the americas: breaking a historical legacy of slavery | Q33308753 | ||
| Two approaches to discovering and developing new drugs for Chagas disease. | Q33503274 | ||
| Community-directed interventions for priority health problems in Africa: results of a multicountry study | Q33965585 | ||
| A new class of anthelmintics effective against drug-resistant nematodes | Q34761361 | ||
| Dracunculiasis eradication: neglected no longer. | Q34847825 | ||
| Filariasis: new drugs and new opportunities for lymphatic filariasis and onchocerciasis | Q34870696 | ||
| Progress towards a dengue vaccine | Q35009119 | ||
| Research for control: the onchocerciasis experience | Q35709561 | ||
| Second-generation vaccines against leishmaniasis | Q36101424 | ||
| Ivermectin and onchocerciasis: is it all solved? | Q36320403 | ||
| Hookworm vaccines: past, present, and future | Q36635886 | ||
| Neglected diseases, civil conflicts, and the right to health | Q36914039 | ||
| Can visceral leishmaniasis be eliminated from Asia? | Q37204166 | ||
| Buruli ulcer disease: prospects for a vaccine | Q37387041 | ||
| Insect vectors of Leishmania: distribution, physiology and their control | Q37402836 | ||
| Schistosomiasis and neglected tropical diseases: towards integrated and sustainable control and a word of caution | Q37470553 | ||
| An assessment of interactions between global health initiatives and country health systems | Q37525469 | ||
| Dengue vaccine candidates in development | Q37608075 | ||
| Trypanocidal drugs: mechanisms, resistance and new targets | Q37623081 | ||
| Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches | Q37629919 | ||
| Complete local elimination of infectious trachoma from severely affected communities after six biannual mass azithromycin distributions | Q37854318 | ||
| Control of human African trypanosomiasis: back to square one | Q38496534 | ||
| Monitoring community-directed treatment programmes for sustainability: lessons from the African Programme for Onchocerciasis Control (APOC). | Q38884280 | ||
| Global framework on essential health R&D. | Q38944845 | ||
| Mass drug administration and integrated control for the world's high-prevalence neglected tropical diseases | Q39078371 | ||
| Neglected tropical disease vaccines | Q39078374 | ||
| Protective effect of the combination BCG vaccination and rifampicin prophylaxis in leprosy prevention | Q39440395 | ||
| Perspectives of vaccination in Chagas disease revisited | Q39945086 | ||
| Elimination of Chagas disease transmission: perspectives | Q39945109 | ||
| Empowering women and improving female reproductive health through control of neglected tropical diseases | Q42630557 | ||
| Waging peace through neglected tropical disease control: a US foreign policy for the bottom billion | Q43199516 | ||
| Topical chemotherapy for experimental murine African CNS-trypanosomiasis: the successful use of the arsenical, melarsoprol, combined with the 5-nitroimidazoles, fexinidazole or MK-436. | Q46910544 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e718 | |
| P577 | publication date | 2010-05-25 | |
| P1433 | published in | PLoS Neglected Tropical Diseases | Q3359737 |
| P1476 | title | "Manifesto" for advancing the control and elimination of neglected tropical diseases | |
| P478 | volume | 4 |
| Q94377912 | Q94377912 |
| Q30419953 | "Barriers" to child development and human potential: the case for including the "neglected enteric protozoa" (NEP) and other enteropathy-associated pathogens in the NTDs |
| Q89547395 | "Buruli ulcer and leprosy, they are intertwined": Patient experiences of integrated case management of skin neglected tropical diseases in Liberia |
| Q64947379 | A novel praziquantel solid lipid nanoparticle formulation shows enhanced bioavailability and antischistosomal efficacy against murine S. mansoni infection. |
| Q35031953 | A patient with erythema nodosus leprosum and Chagas cardiopathy: challenges in patient management and review of the literature |
| Q28482492 | A research agenda for helminth diseases of humans: basic research and enabling technologies to support control and elimination of helminthiases |
| Q39467299 | Algorithmic Mapping and Characterization of the Drug-Induced Phenotypic-Response Space of Parasites Causing Schistosomiasis |
| Q38383115 | Application of GIS technology in public health: successes and challenges. |
| Q35790744 | Biological Activities and Chemical Composition of Methanolic Extracts of Selected Autochthonous Microalgae Strains from the Red Sea. |
| Q39002539 | Camelid Single-Domain Antibodies As an Alternative to Overcome Challenges Related to the Prevention, Detection, and Control of Neglected Tropical Diseases. |
| Q21146700 | Challenges and opportunities associated with neglected tropical disease and water, sanitation and hygiene intersectoral integration programs |
| Q39534299 | Comparison of novel and existing tools for studying drug sensitivity against the hookworm Ancylostoma ceylanicum in vitro. |
| Q33892471 | Drug discovery and development for neglected diseases: the DNDi model |
| Q39712345 | Drugs for Neglected Diseases initiative model of drug development for neglected diseases: current status and future challenges |
| Q44544936 | Drugs for neglected diseases: part I. |
| Q34314514 | Effects of Cu/Zn superoxide dismutase (sod1) genotype and genetic background on growth, reproduction and defense in Biomphalaria glabrata |
| Q28299316 | Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, tribendimidine, and praziquantel in patients with Opisthorchis viverrini: a randomised, exploratory, open-label, phase 2 trial |
| Q26765026 | Eliminating the Neglected Tropical Diseases: Translational Science and New Technologies |
| Q34297640 | Emerging and reemerging neglected tropical diseases: a review of key characteristics, risk factors, and the policy and innovation environment |
| Q37970526 | Enlarging the "Audacious Goal": elimination of the world's high prevalence neglected tropical diseases |
| Q34630487 | Evaluation of the European foundation initiative into African research in neglected tropical diseases by the African fellows. |
| Q38977322 | Factors affecting illness in the developing world: chronic disease, mental health and traditional medicine cures |
| Q89957000 | Harnessing the gut microbiome in the fight against anthelminthic drug resistance |
| Q60031608 | High Throughput and Computational Repurposing for Neglected Diseases |
| Q28478581 | In vitro and in vivo efficacy of Monepantel (AAD 1566) against laboratory models of human intestinal nematode infections |
| Q55459515 | Innovation in neglected tropical disease drug discovery and development. |
| Q64083797 | Intestinal NF-κB and STAT signalling is important for uptake and clearance in a Drosophila-Herpetomonas interaction model |
| Q27028101 | Is dengue a disease of poverty? A systematic review |
| Q33981546 | Linking global HIV/AIDS treatments with national programs for the control and elimination of the neglected tropical diseases |
| Q55378354 | Multiple Sclerosis in the Asia Pacific Region: A Systematic Review of a Neglected Neurological Disease. |
| Q21562238 | NTDs V.2.0: "blue marble health"--neglected tropical disease control and elimination in a shifting health policy landscape |
| Q28749509 | Neglected Tropical Disease Control in the “Post-American World” |
| Q38237279 | Neglected tropical disease and emerging infectious disease: an analysis of the history, promise and constraints of two worldviews |
| Q34321702 | Neglected tropical diseases as hidden causes of cardiovascular disease |
| Q33927439 | New antipoverty drugs, vaccines, and diagnostics: a research agenda for the US President's Global Health Initiative (GHI). |
| Q38163392 | Overcoming the challenges of drug discovery for neglected tropical diseases: the A·WOL experience |
| Q36026850 | Peroxiredoxins in parasites. |
| Q35989698 | Preventive Chemotherapy Versus Innovative and Intensified Disease Management in Neglected Tropical Diseases: A Distinction Whose Shelf Life Has Expired |
| Q34173302 | Quantification and clustering of phenotypic screening data using time-series analysis for chemotherapy of schistosomiasis. |
| Q40151459 | Responding to Ebola: The role of medical journals during global public health emergencies |
| Q26825672 | Reviewing dengue: still a neglected tropical disease? |
| Q27680126 | Structural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke Schistosoma mansoni |
| Q47236154 | Synthetic Biology and the Translational Imperative |
| Q24612180 | Taenia asiatica: the most neglected human Taenia and the possibility of cysticercosis |
| Q28548415 | Targeting Lysine Deacetylases (KDACs) in Parasites |
| Q43216231 | The Four Horsemen of the Apocalypse: Tropical Medicine in the Fight against Plague, Death, Famine, and War. |
| Q92912352 | The antioxidants resveratrol and N-acetylcysteine enhance anthelmintic activity of praziquantel and artesunate against Schistosoma mansoni |
| Q38238051 | The drug and vaccine landscape for neglected diseases (2000-11): a systematic assessment |
| Q39157853 | The neglected |
| Q45338942 | The poverty-related neglected diseases: Why basic research matters |
| Q39201937 | The role of estradiol metabolism in urogenital schistosomiasis-induced bladder cancer. |
| Q36185174 | Threats from emerging and re-emerging neglected tropical diseases (NTDs). |
| Q38901429 | Toward the development of dual-targeted glyceraldehyde-3-phosphate dehydrogenase/trypanothione reductase inhibitors against Trypanosoma brucei and Trypanosoma cruzi. |
| Q33955401 | Unleashing "civilian power": a new American diplomacy through neglected tropical disease control, elimination, research, and development |
| Q30488737 | Using Co-authorship Networks to Map and Analyse Global Neglected Tropical Disease Research with an Affiliation to Germany |
| Q30425005 | Vaccines to combat the neglected tropical diseases |
| Q58856250 | Valeriana wallichii root extracts and fractions with activity against Leishmania spp |
| Q36421227 | Verifying elimination programs with a special emphasis on cysticercosis endpoints and postelimination surveillance |
Search more.